Letters to the editor: March 6, 2006

Johnson & Johnson announced results from its phase 3 GRAVITI trial exploring guselkumab’s results in subcutaneous (SC) induction and maintenance therapy for treating Chron’s disease.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the state level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the federal level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

Melody Hartzler, PharmD, discusses common metabolic roadblocks to weight loss and what tools pharmacy teams can use to identify and address them.

A conversation with Sean Jeffery, PharmD, BCGP, FASCP, AGSF, director of pharmacy at Hartford HealthCare Integrated Care Partners and professor of pharmacy practice at the University of Connecticut.